



OFFICE OF THE CONTROLLER OF EXAMINATIONS
GANGADHAR MEHER UNIVERSITY, SAMBALPUR

No. 11465 / GMU / EC

Date: 30/01/2024

NOTICE

The Ph.D. Scholars who are working on human beings or proposed to work on human beings are requested to apply in prescribed format for ethical clearance from Institutional Ethical Committee of the University. The application should be submitted to Controller of Examinations on or before 28.02.2024 for further action at this end.

for *Spati* 30.1.24
Controller of Examinations
G.M. University, Sambalpur
G.M. University, Sambalpur

Memo No. 11466 / GMU

Date: 30/01/2024

Copy to All Notice Boards / PA to VC / PA to Registrar / Chairman, PGC / Dean, Research / Dy. Registrar / Chairman, DRCs / All HODs / All Supervisors for information and necessary action.

for *Spati* 30.1.24
Controller of Examinations
G.M. University, Sambalpur
G.M. University, Sambalpur

APPLICATION FORM

Institutional Ethics Committee (IEC) for Human Research

(To be filled in by the Principal Investigator / Research Scholar for submission to Institutional Ethics Committee)

1. Name, designation and address of :

Principal Investigator / Research Scholar
(Attach a curriculum vitae of PI / RS)

2. Proposed title of the research work :

3. Brief description of the proposal : (Attach separate sheet with maximum 500 words)

4. Type of study (Tick appropriately) :

Clinical		Single centre	
Behavioral		Multi centric	
Epidemiological		Others	

5. Status of Review :

New		Revised	
-----	--	---------	--

6. Clinical Trials :

(i) Does the study involve use of :

Drug		Indian Systems of Medicine/ Alternate System of Medicine	
Devices		Any other	
Vaccines		Not applicable	

(ii) Is it approved and marketed :

In India		USA	
UK & Europe		Other countries, specify	

(iii) Does it involve a change in use, dosage, route of administration? :

Yes		No	
-----	--	----	--

If yes, whether DCGI's/Any other Regulatory authority's permission is obtained? :

Yes		No	
-----	--	----	--

If yes, Date of permission :

(iv) Is it an Investigational New Drug? :

Yes		No	
-----	--	----	--

If yes, IND No.:

(a) Investigator's Brochure submitted :

Yes		No	
-----	--	----	--

(b) *In vitro* studies data :

Yes		No	
-----	--	----	--

(c) Preclinical Studies done :

Yes		No	
-----	--	----	--

(d) Clinical Study is :

Phase I		Phase III	
Phase II		Phase IV	

(e) Are you aware if this study / similar study is being done elsewhere?
If Yes, attach details

Yes		No	
-----	--	----	--

7. Subject selection (Tick the appropriate boxes)

(i) Number of Subjects

(ii) Duration of study

(iii) Will subjects from both sexes be required

Yes		No	
-----	--	----	--

(iv) Inclusion/exclusion criteria given

Yes		No	
-----	--	----	--

(v) Type of subjects

Volunteers		Patients	
------------	--	----------	--

(vi) Vulnerable subjects

Yes		No	
-----	--	----	--

Pregnant women		Elderly	
Fetus		Handicapped	
Terminally ill		Mentally challenged	
Children		Economically & socially backward	
Illiterate		Any other	
Seriously ill			

(vii) Special group subjects

If Yes,

Yes		No	
-----	--	----	--

Captive		Nurses/dependent staff	
Students		Employees	
Any other		Armed forces	
Institutionalized			

8. Consent

*Written		Oral	
Audio-visual			
* If written consent is not obtained give reasons	:		

(i) Consent form: (Tick the included elements)

Understandable language	
Statement that study involve research	
Sponsor of study	
Purpose and procedures	
Risks & Discomforts	
Benefits	
Confidentiality of records	
Contact information	
Statement that consent is voluntary	
Right to withdraw	
Consent for future use of biological material	

9.	Privacy and confidentiality	:		
(i)	Study involves	:	Direct Identifiers	
			Indirect Identifiers / coded	
			Completely anonymised / delinked	
(ii)	Confidential handling of data by staff	:	Yes	No
10.	Will any advertising be done for recruitment of Subjects? (Posters, flyers, brochure, websites - if so kindly attach a copy)	:	Yes	No
11.	Use of biological/hazardous materials	:		
(i)	Use of fetal tissue or abortus	:	Yes	No
(ii)	Use of organs or body fluids	:	Yes	No
(iii)	Use of recombinant/gene therapy	:	Yes	No
	If yes, has Department of Biotechnology (DBT) approval for rDNA products been obtained?	:	Yes	No
(iv)	Use of pre-existing/stored/left over samples	:	Yes	No
(v)	Collection for banking/future research	:	Yes	No
(vi)	Use of ionizing radiation / radioisotopes	:	Yes	No
	If yes, has Bhaba Atomic Research Centre (BARC) approval for Radioactive Isotopes been obtained?	:	Yes	No
(vii)	Use of Infectious / bio-hazardous specimens	:	Yes	No
	If yes, justify with details of collaborators			
	(a) Is the proposal being submitted for clearance from Health Ministry's Screening Committee (HMSC) for International collaborations?			
(viii)	Proper disposal of material	:	Yes	No
12.	Risks & Benefits	:		
(i)	Is the risk reasonable compared to the anticipated benefits to subjects / community / country?	:	Yes	No
(ii)	Is there physical / social / psychological risk / discomfort? If Yes,	:	Yes	No
			Minimal or no risk	
			More than minimum risk	
			High risk	
(iii)	Is there a benefit			
	(a) To the subject	:	Direct	Indirect
	(b) Benefit to society	:	Yes	No

13. Data Monitoring :

(i) Is there a data & safety monitoring committee / Board? (DSMB)? :

Yes		No	
-----	--	----	--

(ii) Is there a plan for reporting of adverse events? :

Yes		No	
-----	--	----	--

If Yes, reporting is done to :

Sponsor	
Ethics Committee	
DSMB	

(iii) Is there a plan for interim analysis of data? :

Yes		No	
-----	--	----	--

(iv) Are there plans for storage and maintenance of all trial data base? :

Yes		No	
-----	--	----	--

If Yes, for how long

14. Is there compensation for participation? :

Yes		No	
-----	--	----	--

If Yes, :

Monetary		In kind	
Specify amount and type:			

15. Is there compensation for injury? :

Yes		No	
-----	--	----	--

If Yes, :

By sponsor		By Investigator	
By insurance company		By any other	

16. Do you have conflict of interest? :

Yes		No	
-----	--	----	--

If Yes, specify:

Financial	
Non-financial	

Place: _____

Date: _____

Signature of Applicant

CONSENT FORM

(To be obtained from participants)

I am willing to participate in the research work carried out by _____

He / they has/have already given me all information about his /their research work
entitled _____

My participation in the study is entirely voluntary.

1.	Name of participant	:	
2.	Address	:	
3.	Telephone No.	:	
4.	Email ID, if any	:	

Place _____
Date _____

Signature of the participant

Signature & name of witness
Date _____

Signature & name of the person
obtaining consent
Date _____

INFORMATION SHEET

(To be supplied by Principal Investigator)

1.	Name of the Principal investigator / Research scholar	:	
2.	Address	:	
3.	Proposed title of the research work	:	
4.	Voluntary participation	:	
5.	Procedure	:	
6.	Duration	:	
7.	Side effects	:	
8.	Risk	:	
9.	Benefits	:	
10.	Confidentiality	:	
11.	Sharing the result	:	
12.	Right to refuse or withdraw	:	
13.	Whom to contact	:	

Name & designation of Principal Investigator / Research Scholar
Contact No. _____
Email ID _____